Dr. Peter Webborn
Scientific Advisory Board
drug discovery and development
ImaBiotech
France
Biography
Pete Webborn has over 30 years of experience of drug discovery and development in the pharmaceutical industry. He has worked in the UK, US and Sweden. His particular areas on interest include prediction of Pharmacokinetic properties, physicochemical properties as determinants of drug clearance and distribution, and the use of PKPD modelling to help understand therapeutic utility. From 2011 he led the internalisation, development, and integration of AstraZeneca’s mass spectrometry imaging capability, bringing new insights to projects about drug distribution in relation to biological effects. In 2016 he left AstraZeneca and now works as an independent consultant, supporting Biotech and Pharma. He has published over 30 papers and was a recipient of the Royal Society of Chemistry, Malcolm Campbell medal in 2013 for his work on the discovery of Brilinta.
Research Interest
drug discovery and development
